Mereo BioPharma (MREO) Operating Expenses (2023 - 2026)

Mereo BioPharma (MREO) has reported Operating Expenses for 4 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses fell 21.75% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.3 million (down 21.22% YoY) and the FY2025 annual result came in at $40.8 million, down 13.91% from the prior year.
• Operating Expenses improved to $8.8 million in Q1 2026 per MREO's latest filing, from $8.4 million in the prior quarter.
• Over the last five years, Operating Expenses for MREO reached as high as $15.3 million in Q4 2024 and fell as low as $8.4 million in Q4 2025.
• A 4-year average of $10.5 million and a median of $10.1 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 81.82% — and 2025, when it plunged 45.07%.
• Year by year, Operating Expenses stood at $8.4 million in 2023, then jumped by 81.82% to $15.3 million in 2024, then plunged by 45.07% to $8.4 million in 2025, then climbed by 4.48% to $8.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $8.8 million, $8.4 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.